General

Showing 2225–2240 of 2270 results

Article: Updated BHS guidelines for the treatment of chronic lymphocytic leukaemia, mantle cell lymphoma and Waldenström macroglobulinemia anno 2018
€3.03 Add to cart
Article: Updated BHS guidelines for the treatment of diffuse large B-cell lymphoma (DLBCL): Novelties anno 2024
€3.03 Add to cart
Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma
€3.03 Add to cart
Article: Updated results of the TAGS trial reinforce the clinical benefit and safety of TAS-102 in patients with advanced gastric cancer
€3.03 Add to cart
Article: Updated survival data on maintenance therapy with olaparib in patients with platinum-sensitive recurrent ovarian cancer
€3.03 Add to cart
Article: Updates on melanoma
€3.03 Add to cart
Article: Use of multiparameter flow cytometry in multiple myeloma and other plasma cell neoplasms
€3.03 Add to cart
Article: Vaccination guidelines in haematopoietic transplant patients: recommendations from the BHS Transplant Committee
€3.03 Add to cart
Article: Vaccination policy in adult patients with hematological malignancies or asplenia without stem cell transplantation: Recommendations from the advisory board on vaccination of the Belgian Hematological Society
€3.03 Add to cart
Article: Vaccine response in patients receiving anti-B-cell targeted therapy
€3.03 Add to cart
Article: Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS syndrome) with multiple thromboembolism events: A Belgian case report
€3.03 Add to cart
Article: Validation of a ready to use Clauss fibrinogen
€3.03 Add to cart
Article: Value and implications of the anti-Xa activity monitoring in pregnant women receiving prophylactic LMWH: a retrospective study
€3.03 Add to cart
Article: Vascular safety profile of new generation BCR-ABL tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia
€3.03 Add to cart
Article: Venetoclax-Azacitidine, the new standard of care for AML patients unfit for intensive treatment: A guide for clinical practice
€3.03 Add to cart
Article: Venetoclax-rituximab induces deep responses in relapsed CLL
€3.03 Add to cart

Article: Updated BHS guidelines for the treatment of chronic lymphocytic leukaemia, mantle cell lymphoma and Waldenström macroglobulinemia anno 2018

Article: Updated BHS guidelines for the treatment of diffuse large B-cell lymphoma (DLBCL): Novelties anno 2024

Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma

Article: Updated results of the TAGS trial reinforce the clinical benefit and safety of TAS-102 in patients with advanced gastric cancer

Article: Updated survival data on maintenance therapy with olaparib in patients with platinum-sensitive recurrent ovarian cancer

Article: Updates on melanoma

Article: Use of multiparameter flow cytometry in multiple myeloma and other plasma cell neoplasms

Article: Vaccination guidelines in haematopoietic transplant patients: recommendations from the BHS Transplant Committee

Article: Vaccination policy in adult patients with hematological malignancies or asplenia without stem cell transplantation: Recommendations from the advisory board on vaccination of the Belgian Hematological Society

Article: Vaccine response in patients receiving anti-B-cell targeted therapy

Article: Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS syndrome) with multiple thromboembolism events: A Belgian case report

Article: Validation of a ready to use Clauss fibrinogen

Article: Value and implications of the anti-Xa activity monitoring in pregnant women receiving prophylactic LMWH: a retrospective study

Article: Vascular safety profile of new generation BCR-ABL tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia

Article: Venetoclax-Azacitidine, the new standard of care for AML patients unfit for intensive treatment: A guide for clinical practice

Article: Venetoclax-rituximab induces deep responses in relapsed CLL